ConvaTec Group - Public Comps and Valuation Multiples

ConvaTec Group Overview

About ConvaTec Group

Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.

Founded

2016

HQ

Employees

10.1K+

Website

convatecgroup.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue $1.8B

LTM EBITDA $461M

EV

$7.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

ConvaTec Group Financials

ConvaTec Group has a last 12-month revenue of $1.8B and a last 12-month EBITDA of $461M.

In the most recent fiscal year, ConvaTec Group achieved revenue of $2.7B and an EBITDA of $573M.

ConvaTec Group expects next 12-month revenue of XXX and NTM EBITDA of XXX

See ConvaTec Group valuation multiples based on analyst estimates

ConvaTec Group P&L

	FY 2022	FY 2023	FY 2024	LTM	NTM
Revenue	$2.6B	$2.7B	$2.3B	$1.8B	XXX
Gross Profit	$1.4B	$1.4B	$1.5B	XXX	XXX
Gross Margin	54%	52%	66%	XXX	XXX
EBITDA	$448M	$573M	$573M	$461M	XXX
EBITDA Margin	17%	21%	25%	25%	XXX
Net Profit	$148M	$79.1M	$164M	XXX	XXX
Net Margin	6%	3%	7%	XXX	XXX
Net Debt	$1.1B	$1.3B	$1.4B	XXX	XXX

Financial data powered by Morningstar, Inc.

ConvaTec Group Stock Performance

As of February 21, 2025, ConvaTec Group's stock price is GBP 2 (or $3).

ConvaTec Group has current market cap of GBP 5.1B (or $6.4B), and EV of GBP 6.1B (or $7.7B).

See ConvaTec Group trading valuation data

ConvaTec Group Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$7.7B	$6.4B	XXX	XXX	XXX	XXX	$0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

ConvaTec Group Valuation Multiples

As of February 21, 2025, ConvaTec Group has market cap of $6.4B and EV of $7.7B.

ConvaTec Group's trades at 3.3x LTM EV/Revenue multiple, and 13.2x LTM EBITDA.

Analysts estimate ConvaTec Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for ConvaTec Group and 10K+ public comps

ConvaTec Group Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$7.7B	XXX	XXX	XXX
EV/Revenue	3.4x	XXX	XXX	XXX
EV/EBITDA	13.4x	XXX	XXX	XXX
P/E	20.9x	XXX	XXX	XXX
P/E/Growth	1.5x	XXX	XXX	XXX
EV/FCF	28.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ConvaTec Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

ConvaTec Group Valuation Multiples

ConvaTec Group's NTM/LTM revenue growth is 4%

ConvaTec Group's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, ConvaTec Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate ConvaTec Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for ConvaTec Group and other 10K+ public comps

ConvaTec Group Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	-15%	XXX	XXX	XXX	XXX
EBITDA Margin	25%	XXX	XXX	XXX	XXX
EBITDA Growth	0%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	29%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.3M	XXX	XXX	XXX	XXX
Opex per Employee	$0.1M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	29%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	10%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	5%	XXX	XXX	XXX	XXX
Opex to Revenue	44%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Medical Devices

Consumer SaaS

Streaming Platforms

AdTech Software

Climate Tech

GRC Software

Developer Tools

Explore Valuation Multiples by Industry